2011
DOI: 10.1007/s12072-011-9282-y
|View full text |Cite
|
Sign up to set email alerts
|

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection

Abstract: TDF has the makings of an "ideal" first-line drug for the treatment of CHB.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2012
2012
2014
2014

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 80 publications
0
1
0
Order By: Relevance
“…). Moreover, the results reported here confirm that antiviral therapy with nucleos(t)ide analogs (TDF in this case), which can dramatically reduce serum HBV DNA , had a minimal impact on serum HBcAg (empty virion) levels in most patients even after years of potent HBV DNA suppression. These results were expected because most nucleos(t)ide analog‐treated patients do not clear hepatic cccDNA, which drives the HBcAg and HBsAg expression sufficient for empty virion secretion, even in the absence of viral DNA synthesis (Fig.…”
Section: Discussionmentioning
confidence: 99%
“…). Moreover, the results reported here confirm that antiviral therapy with nucleos(t)ide analogs (TDF in this case), which can dramatically reduce serum HBV DNA , had a minimal impact on serum HBcAg (empty virion) levels in most patients even after years of potent HBV DNA suppression. These results were expected because most nucleos(t)ide analog‐treated patients do not clear hepatic cccDNA, which drives the HBcAg and HBsAg expression sufficient for empty virion secretion, even in the absence of viral DNA synthesis (Fig.…”
Section: Discussionmentioning
confidence: 99%